Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)

AIDS

Volumn 15, Issue 15, 2001, Pages 1951-1957

  Eshleman, Susan H ^a   Mracna, Martin ^a   Guay, Laura A ^a   Deseyve, Martina ^b   Cunningham, Shawn ^a   Mirochnick, Mark ^c   Musoke, Philippa ^d   Fleming, Thomas ^e   Fowler, Mary Glenn ^f   Mofenson, Lynne M ^g   Mmiro, Francis ^d   Jackson, J Brooks ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Clinical trial; Drug resistance; Genotype; HIV 1; Infant; Nevirapine; Pregnancy; Prophylaxis; Uganda; Vertical transmission

Indexed keywords

CD4 ANTIGEN; NEVIRAPINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; UGANDA; VERTICAL TRANSMISSION; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INFANT; INFANT, NEWBORN; MUTATION; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035913939     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200110190-00006     Document Type: Article

References (11)

1. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial
2. The one year safety and efficacy data of the HIVNET 012 trial
3. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
4. Identification of the K103N mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
5. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)
6. Analysis of HIV-1 protease and reverse transcriptase in antiretroviral drug naïve Ugandan adults
7. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates
8. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
9. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy